Stratified analysis by cancer type for these two polymorphisms indicated that the GSTM1 null genotype was significantly associated with increased cancer risks for prostate cancer, colorectal cancer, breast cancer, bladder cancer, lung cancer, ALL, gastric cancer, head and neck cancer, and nasopharyngeal carcinoma. This evidence concerns the gene GSTM1 and nasopharyngeal carcinoma.